Novartis AG filed a Form 6-K with the SEC on November 19, 2026, disclosing updated mid-term financial guidance and upgraded peak sales projections for multiple in-market brands, as presented at the Meet Novartis Management event in London.
Key Highlights
- +5% cc sales CAGR: Net sales are expected to grow at a +5% constant-currency CAGR from 2026 to 2031, according to the filing.
- Core operating income margin target: Core operating income margin is described as "on track to return to 40%+ by 2029."
- Kesimpta peak sales raised: Guidance upgraded from USD 6 billion to USD 8 billion.
- Scemblix and Leqvio peak sales raised: Both upgraded from USD 4 billion to USD 5 billion each.
- Nine in-market assets: Novartis reported nine de-risked, in-market assets with peak sales potential of USD 3-10 billion, including Kisqali, Rhapsido, Cosentyx, Kesimpta, Pluvicto, Scemblix, Leqvio, the Zolgensma Group, and Fabhalta.
- Pipeline readouts: The company disclosed 35+ potentially submission-enabling readouts expected through 2031, with 10 late-stage assets carrying multi-billion-dollar peak sales guidance.
Novartis Mid-Term Outlook and Brand Guidance Updates
According to the Form 6-K, Novartis rolled forward its mid-term guidance to cover the period 2026 to 2031, projecting net sales growth at a +5% constant-currency compound annual growth rate. The company also disclosed that its core operating income margin is "on track to return to 40%+ by 2029." The filing stated that the updated outlook reflects "continued momentum from in-market growth drivers as well as upcoming launches," and was presented at the Meet Novartis Management event in London on November 19, 2026.
The filing disclosed upgraded peak sales guidance for three in-market brands. Kesimpta's peak sales guidance was raised from USD 6 billion to USD 8 billion. Both Scemblix and Leqvio were raised from USD 4 billion to USD 5 billion each. The filing noted these follow a recent upgrade for Rhapsido/remibrutinib to USD 8 billion across chronic spontaneous urticaria, chronic inducible urticaria, and relapsing multiple sclerosis, with what the filing described as "additional multi-billion-dollar potential across all other indications." Novartis reported that it now has nine de-risked, in-market assets with peak sales potential of USD 3-10 billion.
Beyond the in-market portfolio, the filing disclosed a pipeline of 30+ potential high-value assets across four core therapeutic areas and three advanced technology platforms, with 20+ in registration, Phase III, or Phase II, and 10+ in or entering Phase I. Select pipeline assets highlighted include abelacimab in atrial fibrillation, GHZ339 in atopic dermatitis, del-brax for facioscapulohumeral muscular dystrophy, votoplam for Huntington's disease, and pelabresib in myelofibrosis. The filing contains forward-looking statements that, as noted in the filing's disclaimer, are subject to significant known and unknown risks and uncertainties.
What Was Disclosed
Novartis filed a Form 6-K on November 19, 2026, disclosing updated 2026-2031 sales growth guidance of +5% cc CAGR, a core margin target of 40%+ by 2029, raised peak sales guidance for Kesimpta, Scemblix, and Leqvio, and details on its pipeline and in-market asset portfolio.





Please wait processing your request...